Advertisement
UK markets close in 6 hours 57 minutes

  • FTSE 100

    8,093.76
    +53.38 (+0.66%)
     

  • FTSE 250

    19,685.47
    -33.90 (-0.17%)
     

  • AIM

    754.63
    -0.06 (-0.01%)
     

  • GBP/EUR

    1.1669
    +0.0024 (+0.21%)
     

  • GBP/USD

    1.2518
    +0.0056 (+0.45%)
     

  • Bitcoin GBP

    51,115.02
    -2,169.76 (-4.07%)
     

  • CMC Crypto 200

    1,364.40
    -18.17 (-1.31%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.24
    +0.43 (+0.52%)
     

  • GOLD FUTURES

    2,337.90
    -0.50 (-0.02%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    18,025.85
    -62.85 (-0.35%)
     

  • CAC 40

    8,069.54
    -22.32 (-0.28%)
     
Property:

How to sell your home

Top tips from property investors

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

Business Insider UK
Updated
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

Thomson Reuters

ZURICH (Reuters) - Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Novartis, which said the deal includes additional payments, royalties and fees pending the achievement of milestones, already has a blockbuster drug, Cosentyx, in immunology with accelerating sales in psoriasis and ankylosing spondolitis.

(Reporting by John Miller; Editing by Jan Harvey)

See Also: